The chief development officer at Spinogenix shared initial results from the first cohort of the company’s phase 2 trial assessing SPG302 in Alzheimer disease presented at AAIC 2025. [WATCH TIME: 6 minutes]
Sharron Gargosky, PhD
Advertisement
Chief development officer at Spinogenix.
Articles by Sharron Gargosky, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Showcasing Sustained Benefits in Myasthenia Gravis Research at AANEM 2025: Kimberly Moran, PhD, MBA
2
This Week on NeurologyLive® — November 3, 2025
3
Alexander Gold, MD, on Adrabetadex’s Impact in Infantile-Onset Niemann-Pick C
4
Exploring Long-Term Efficacy of Inebilizumab in Phase 3 Myasthenia Gravis Trial: Richard Nowak, MD, MS
5
